A study, published in the Archives of Neurology, showed that measurement of two biomarker levels in stroke survivors may provide predictive information for recurrent ischemic stroke beyond traditional risk factors.

The two biomarkers are soluble vascular cell adhesion molecule 1 ( sVCAM-1 ) and N-terminal pro-B-type natriuretic peptide ( NT-proBNP ).
These biomarkers along with C-reactive protein, homocysteine, renin and lipids and lipoprotein particle concentration and size were measured in 252 participants with cerebrovascular disease, a sub-group, of the Perindopril Protection Against Recurrent Stroke Study ( PROGRESS ).

These participants had experienced ischemic stroke during the follow-up period of the study and were matched to control patients who did not have a stroke. PROGRESS was a placebo-controlled trial of a Perindopril erbumine-based, blood pressure-lowering regimen that reduced ischemic stroke risk by 24 percent among individuals with previous stroke or transient ischemic attack. Ischemic stroke is the most common kind of stroke caused by an interruption of blood flowing to the brain.

The patients with stroke or transient ischemic attack are at high risk of another stroke, and there is need for improved strategies to predict recurrent stroke.
Stroke is a leading cause of death and disablement, with a risk of 21 percent for people 55 years of age or older.

Duncan J. Campbell, from St. Vincent's Institute of Medical Research, Fitzroy, Australia, and colleagues analyzed the findings.

" Patients in the highest quarters for both sVCAM-1 and NT-proBNP levels had 3.6 times the risk of recurrent ischemic stroke compared with patients in the lowest quarters for both biologic markers," the researchers found. " Level of sVCAM-1 was similarly predictive of ischemic stroke in patients allocated to placebo and Perindopril-based therapy. Baseline plasma levels of C-reactive protein, homocysteine, renin, and lipids and lipoprotein particle concentration and size did not predict recurrent ischemic stroke risk."

In conclusion the authors write, " Characterization of the mechanisms of ischemic stroke pathogenesis associated with increased sVCAM-1 level may lead to development of therapies that provide benefits additional to those provided by angiotensin-converting enzyme inhibitor-based ( ACE-inhibitors ), blood pressure lowering therapies."

Source: American Medical Association, 2005


XagenaMedicine2005